Sign up to create alerts for Instruments,
Economic Events and content by followed authors
Free Sign Up Already have an account? Sign In
Manuel Fernández
17 hours ago
With presidencial elections, this value in 2,30$
0
0
Quotes
All Instrument Types
- All Instrument Types
- Indices
- Equities
- ETFs
- Funds
- Commodities
- Currencies
- Crypto
- Bonds
- Certificates
Please try another search
📈 Free Gift Friday: Instantly Copy Legendary Investors' Portfolios Copy for Free
1.320
+0.010
+0.76%
- Real-time Cboe. Currency in USD ( Disclaimer )
Type:
Equity
Market:
United States
- Volume: 856
- Bid/Ask: 0.000 / 0.000
- Day's Range: 1.320 - 1.380
Hepion Pharmaceuticals
1.320
+0.010
+0.76%
- General
- Chart
- News & Analysis
- Financials
- Technical
- Forum
- Overview
- Profile
- Historical Data
- Index Component
Hepion Pharmaceuticals Inc Company Profile
Get an in-depth profile of Hepion Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Contact Information
Address
399 Thornall Street First Floor
Edison, 08837
United States
Edison, 08837
United States
Phone
732 902 4000
Fax
732 902 4100
Top Executives
| Name | Age | Since | Title |
|---|---|---|---|
| Timothy M. Block | 69 | 2013 | Independent Director |
| Philippe Gallay | - | 2016 | Member of Scientific Advisory Board |
| John Patrick Brancaccio | 76 | 2013 | Independent Chairman |
| Nikolai V. Naoumov | - | 2023 | Member of Scientific Advisory Board |
| Kaouthar Lbiati | 45 | 2022 | Independent Director |
| Rohit Loomba | - | 2023 | Member of Scientific Advisory Board |
| Yury V. Popov | - | 2023 | Member of Scientific Advisory Board |
| Vlad Raziu | - | 2023 | Member of Scientific Advisory Board |
| Stephen A. Harrison | - | 2019 | Scientific Advisory Board Chair & Consultant Medical Director |
| Michael J. Purcell | 66 | 2024 | Director |
Write your thoughts about Hepion Pharmaceuticals Inc
Are you sure you want to delete this chart?
Delete Cancel
Replace the attached chart with a new chart ?
Replace Cancel
Comment Guidelines
Manuel Fernández
17 hours ago
In four mounths with price of 2,20$
0
0
stats con chris
Apr 19, 2024 5:24PM ET
below 2 USD is fulfilled. As said previously, Hepion key price was 2, from there it tried to move up in a desperate move but eventually on Apr 19 it went down to 1.3. global market is finally in a down trend and pushing hepion down. Good entry point is 1 due to a second desperate that will appear at such level. Enjoy
0
0
stats con chris
Jan 26, 2024 8:39PM ET
2USD fulfilled..unluckily S&P is at record high...which means that a reversal is coming soon and therefore hepion is meant to fall even more..maybe goes from 2 to 3 in a desperate move but global tren will push it to 1. We come back to hepion in july...big month due to presidential elections
1
0
Chiaretto Calo
Nov 28, 2023 10:19AM ET
Hepion Pharmaceuticals is at the forefront of developing treatments for complex diseases like non-alcoholic steatohepatitis (NASH), fibrotic diseases, hepatocellular carcinoma (HCC), and other chronic conditions. The company uses Artificial Intelligence (AI) to drive its therapeutic drug development, which is a modern approach that could revolutionize treatment methodologies in the medical field.
Promising Clinical Trial Results
The company's lead drug, Rencofilstat, has shown promising results in the Phase 2 ALTITUDE-NASH clinical trial. This trial achieved primary and secondary endpoints, including improvement in liver function and multiple NASH biomarkers. Additionally, Hepion Pharmaceuticals announced major reductions in liver stiffness with Rencofilstat treatment in a 17-week Phase 2 study of advanced MASH liver disease. These positive outcomes from clinical trials are strong indicators of the drug's potential efficacy and success.
0
0
stats con chris
Jul 25, 2023 6:29AM ET
Be patient. keep waiting for 2 USD... it will keep going down with fake upward spikes
0
0
stats con chris
May 23, 2023 3:37PM ET
Let's think about it.. When they declared a split the price was 0.7 USD. They needed to hold a 1 USD level to stay in NASDAQ, they needed a +50% growth. They realized that they were not capable of that, which shows that they were aware that their future releases and updates were not going to be sufficient to attrack new investors. Therefore they use a split.. Because of this investors sold their shares and the price fell from 0.7 to 0.5. Then, after the split, it kept falling from 10 to 6, so the real value became 0.3 USD (a disaster). Once real investors sold, insiders and fishy traders decided to buy back the shares up to 20 USD...that is, up to the actual value of 1USD. Because of this alarming price without real suppor for it, now insiders are getting rid of these overvalued stocks selling them to newcomers who think that this is a growing company. Today the price is at 16 USD, that is, around 0.7 USD again. Would they buy more? No way, is an inflated stock, nobody wants to buy an inflated stock without a solid future... Thanks to this move we already know that a good entry point is 6 USD, but due to global consequences it must drop to 2 USD... 2 USD is a good starting point to reset this company from scratch..so until then let's wait
0
0
stats con chris
May 11, 2023 10:04AM ET
Dont buy this... now is at 10 USD after a split 1:20.. real value is 0.5 USD. It will never jump back to 20 USD, HEPA is meant to go back to 2 USD in the future, you will waste money here :D. Every company that splits to remain in NASDAQ fails to increase. of course in the short term it may jump back to 12 or even 15 but the ultimate value in this season is 2 USD... so a total waste....
1
0
stats con chris
May 11, 2023 7:26AM ET
Split reflects that they don't have money nor good results in the coming months to reach the 0.1USD threshold... In simple terms "they suc$k". Sell their trash. Come back when they are back to 2USD...downtrend is so
0
0
stats con chris
Jan 17, 2023 10:52AM ET
hepion's comeback
0
0
Ma Po
Jan 17, 2023 10:52AM ET
any reason?
0
0
stats con chris
Jan 17, 2023 10:52AM ET
they got a nofitication to reach the minium value of 1USD..otherwise they are out of NASDAQ. so they will try to remain above 1... you can read all on their website
0
0
Add Chart to Comment
Confirm Block
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
Report this comment
I feel that this comment is:
Comment flagged
Thank You!
Your report has been sent to our moderators for review